Influenza virus receptors on human airway epithelial cells

人呼吸道上皮细胞上的流感病毒受体

基本信息

  • 批准号:
    10226011
  • 负责人:
  • 金额:
    $ 60.62万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-09-03 至 2024-07-31
  • 项目状态:
    已结题

项目摘要

Influenza virus causes worldwide seasonal infections and occasional pandemics with high mortality rate. Human viruses are known to have a preference for α2-6 linked sialic acids (NeuAcα2-6Gal), while avian viruses exhibit a preference for α2-3 linked sialic acids (NeuAcα2-3Gal). This difference in receptor specificity is widely considered a major species barrier for transmission of avian viruses in the human population. Although this binary model of receptor specificity has been useful, it belies the true complexity of sialic acid containing glycans on host cells and has becoming increasingly limiting since the receptor binding properties of influenza viruses continue to evolve. The use of glycan microarrays with dozens of α2-3 and α2-6 linked glycans has shown that influenza viruses evolve by restricting their specificity to specific glycans within those broad groups. However, interpretation of these findings for their relevance to influenza biology is uncertain since there is little information about the types of glycans that are actually present on human airway epithelium, and whether relevant airway epithelium glycans are represented on glycan microarrays. This project aims to identify the glycan structures on human airway epithelial cells that bind human influenza virus and expand glycan array libraries to include them, 2) to determine how the specificity and activity of human influenza virus hemagglutinins (HAs) and neuraminidases (NAs) evolve under immune selective pressure to retain their ability to interact with human airway receptors and 3) to use the information gleaned about receptor specificity to develop reliable methods for analysis and propagation of influenza in the laboratory. This information will identify receptor determinants on the human airway that are shared by human influenza viruses, and shed light on properties of the HA and NA that contribute to pandemic risk of influenza viruses from avian viruses that occasionally infect humans.
流感病毒在世界范围内引起季节性感染和偶尔的大流行,死亡率很高。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JAMES C PAULSON其他文献

JAMES C PAULSON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JAMES C PAULSON', 18)}}的其他基金

Removing sialic acid ligands of CD28 to enhance T cell cancer immunotherapy
去除CD28的唾液酸配体以增强T细胞癌症免疫治疗
  • 批准号:
    10668007
  • 财政年份:
    2023
  • 资助金额:
    $ 60.62万
  • 项目类别:
Siglec-targeted nanoparticles for treating mast cell mediated allergic disease
Siglec 靶向纳米颗粒用于治疗肥大细胞介导的过敏性疾病
  • 批准号:
    10331726
  • 财政年份:
    2018
  • 资助金额:
    $ 60.62万
  • 项目类别:
Exploiting inhibitory Siglecs for desensitizing mast cells
利用抑制性 Siglecs 使肥大细胞脱敏
  • 批准号:
    10219077
  • 财政年份:
    2018
  • 资助金额:
    $ 60.62万
  • 项目类别:
Exploiting inhibitory Siglecs for desensitizing mast cells
利用抑制性 Siglecs 使肥大细胞脱敏
  • 批准号:
    9789823
  • 财政年份:
    2018
  • 资助金额:
    $ 60.62万
  • 项目类别:
Exploiting inhibitory Siglecs for desensitizing mast cells
利用抑制性 Siglecs 使肥大细胞脱敏
  • 批准号:
    10468007
  • 财政年份:
    2018
  • 资助金额:
    $ 60.62万
  • 项目类别:
Siglec-targeted nanoparticles for treating mast cell mediated allergic disease
Siglec 靶向纳米颗粒用于治疗肥大细胞介导的过敏性疾病
  • 批准号:
    10097996
  • 财政年份:
    2018
  • 资助金额:
    $ 60.62万
  • 项目类别:
Influenza virus receptors on human airway epithelial cells
人呼吸道上皮细胞上的流感病毒受体
  • 批准号:
    9887570
  • 财政年份:
    2015
  • 资助金额:
    $ 60.62万
  • 项目类别:
Influenza virus receptors on human airway epithelial cells
人呼吸道上皮细胞上的流感病毒受体
  • 批准号:
    8963149
  • 财政年份:
    2015
  • 资助金额:
    $ 60.62万
  • 项目类别:
Influenza virus receptors on human airway epithelial cells
人呼吸道上皮细胞上的流感病毒受体
  • 批准号:
    9233896
  • 财政年份:
    2015
  • 资助金额:
    $ 60.62万
  • 项目类别:
Influenza virus receptors on human airway epithelial cells
人呼吸道上皮细胞上的流感病毒受体
  • 批准号:
    10676798
  • 财政年份:
    2015
  • 资助金额:
    $ 60.62万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 60.62万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 60.62万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 60.62万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 60.62万
  • 项目类别:
    Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 60.62万
  • 项目类别:
    Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 60.62万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 60.62万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
  • 批准号:
    10639161
  • 财政年份:
    2023
  • 资助金额:
    $ 60.62万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 60.62万
  • 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 60.62万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了